Regentis Biomaterials (NYSEAMERICAN:RGNT – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.22) earnings per share for the quarter, FiscalAI reports.
Regentis Biomaterials Stock Down 1.7%
Shares of NYSEAMERICAN RGNT opened at $1.93 on Friday. The firm’s 50-day moving average price is $2.26 and its 200-day moving average price is $2.77. Regentis Biomaterials has a 52-week low of $1.23 and a 52-week high of $15.50.
Hedge Funds Weigh In On Regentis Biomaterials
A hedge fund recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC purchased a new stake in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned 5.79% of Regentis Biomaterials as of its most recent SEC filing.
About Regentis Biomaterials
Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.
Further Reading
- Five stocks we like better than Regentis Biomaterials
- Microsoft’s Azure Reporting Shift Adds Clarity, But the Bull Case Came First
- Feed to Feat: Can Meta Unlock the AI Agent Cash Machine?
- Chime Finds Its Stride With a $590M Deal That Could Reshape Its Banking Model
- IBM and Lockheed Martin Turn a Swiss Defense Deal Into a Quantum Computing Bet
Receive News & Ratings for Regentis Biomaterials Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regentis Biomaterials and related companies with MarketBeat.com's FREE daily email newsletter.
